Postby roadrunner » Mon Jan 30, 2023 3:58 pm
I agree with Beach and the others—this is definitely a big win!
In light of your trial team’s excitement, do you know what their specific innovation(s)/differentiation with this trial’s TIL approach is? Also, did they drop any hints as to whether you’re an outlier in their trial, or are they seeing promising results across the board? (I understand they may keep that close.)
7/19: RC: Staged IIIA, T2N1M0
approx 4.25 cm, low/mid rectum, mod. well diff.; lung micronodule
8/19-10/19 4 rds.FOLFOX neoadjuvant, 3 w/Oxiplatin (reduced 70-75%)
neoadjuvant chemorad 11/19
4 rounds FOLFOX July-August 2020
ncCR 10/20; biopsies neg
TAE 11/20, tumor cells removed
Chest CT 3/30/21 growth in 2 nodules (3 and 5mm)
VATS 12/8/21 sub-pleural met 7mm.
SBRT nodule 1/22
6/20/22 TAE rectal polyp benign)
NED from 3/22 - 3/23
4 cycles FOLFIRI
LUL VATS lobectomy for radio resistant met 7/7/23